-
International Journal of Chronic Obstructive Pulmonary Disease
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
The role of combination therapy with corticosteroids and long-acting β2-agonists in the prevention of exacerbations in COPD
(2086) Views (427) Full article downloads
Authors: Mario Cazzola, Nicola A Hanania
Published Date February 2006
Volume 2006:1(4) Pages 345 - 354
DOI: http://dx.doi.org/10.2147/COPD.S
Mario Cazzola1, Nicola A Hanania2
1Antonio Cardarelli Hospital, Department of Respiratory Medicine, Unit of Pneumology and Allergology, Naples, Italy; 2Baylor College of Medicine, Division of Pulmonary and Critical Care Medicine, Houston, TX, USA
Abstract: Acute exacerbations of COPD can complicate the course of the disease in patients with severe airway obstruction. Reduction of exacerbations is an important clinical outcome in evaluating new therapies in COPD. Combination therapies with long-acting β-agonists and inhaled corticosteroids have now been approved for use. Three 1-year randomized clinical trials, which studied the effect of combining a long-acting β2-agonist with an inhaled corticosteroid in COPD, documented that exacerbation frequency was lower with therapy than placebo. Combination therapy had a similar effect to its monocomponents in the trial evaluating salmeterol/fluticasone combination. However, when patients with more severe COPD were studied using a combination of budesonide and formoterol, a clear improvement was seen in the overall exacerbation rates compared with the use of a long-acting β2-agonist alone.
Keywords: COPD, exacerbation, inhaled corticosteroids, inhaled long-acting β2-agonists, budesonide, fluticasone, formoterol, salmeterol, combination therapy
Readers of this article also read:
Cost-effectiveness of smoking cessation and the implications for COPD
Immediate and early discharge for patients with exacerbations of chronic obstructive pulmonary disease: is there a role in “real life”?
Comparison of oxygenation in peripheral muscle during submaximal aerobic exercise, in persons with COPD and healthy, matched-control persons
Pulmonary stem cells and the induction of tissue regeneration in the treatment of emphysema
Influenza: the virus and prophylaxis with inactivated influenza vaccine in “at risk” groups, including COPD patients
Fixed combination therapies in COPD – effect on quality of life
Long-term oxygen therapy: Are we prescribing appropriately?
The influence of the media on COPD patients’ knowledge regarding cardiopulmonary resuscitation
Knowledge and attitudes of family physicians coming to COPD continuing medical education
- Journal Indexing
See where all the Dove Press journals are indexed
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Clinical effectiveness of the Respimat® inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices
- Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity
- The pathophysiology of bronchiectasis
- Exacerbation rate, health status and mortality in COPD – a review of potential interventions




